CTNM

Contineum TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$19.00

+53.5% vs current

Most likely

Base case

45%

Probability

Target price

$13.00

+5.0% vs current

B-

Bear case

25%

Probability

Target price

$8.00

-35.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Evidence quality is good because primary filings and company IR materials are available, but catalyst density is still low and the deterministic prior is neutral-to-slightly negative. Net view is a low-conviction monitoring stance: balance sheet and near-term readout timing are supportive, yet the thesis still hinges on early clinical proof rather than broad operating momentum.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventPIPE-791 chronic pain Phase 1b topline in Q2 2026High impact

Management said topline data from the exploratory PIPE-791 Phase 1b trial in chronic osteoarthritis pain or chronic lower back pain is expected in the second quarter of 2026; the 10-K also frames this study as an efficacy-signal readout for internal development decisions [#PR-2026-03-05][#10-K-2026-03-05].

2026-12-31catalystPROPEL-IPF execution can gradually de-risk the lead programHigh impact

Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 study of PIPE-791 in approximately 324 IPF patients, while the 10-K projects trial completion in June 2028; steady enrollment and clean execution are the main medium-term fundamental supports before efficacy data arrive [#PR-2026-03-05][#10-K-2026-03-05].

2026-12-31catalystBalance sheet reduces near-term financing pressureHigh impact

The company reported $262.9 million of cash, cash equivalents and marketable securities at December 31, 2025, and guided runway through mid-2029 after the December 2025 upsized equity raise, which lowers immediate financing risk while PIPE-791 data mature [#PR-2026-03-05][#10-K-2026-03-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology